Key Proposal of E-cigarette Tax Adjustment in Indonesia

Regulations by 2FIRSTS.ai
Nov.29.2023
Key Proposal of E-cigarette Tax Adjustment in Indonesia
The Indonesian Ministry of Finance proposes revisions to the public health law, including increasing taxes on e-cigarette liquid and combating illegal cigarettes.

According to a report by The New York Times, the Ministry of Finance of Indonesia (Kemenkeu) has recently put forth a series of crucial recommendations aimed at revising the draft public health law. One of the significant proposals involves adjusting the tax rate on e-cigarette liquid and intensifying efforts to combat the illicit tobacco market.

 

The Ministry of Finance has proposed specific measures aimed at standardizing tax collection, curbing the production and sale of illegal cigarettes, and specifying the extent of tax rate adjustments. The objective of this revision is to optimize the public health environment and prevent the exacerbation of social health problems.

 

It should be noted that there will be a stronger crackdown on the issue of illegal cigarettes as emphasized by the Ministry of Finance. Simultaneously, there will be new adjustments to the tax rate for e-cigarettes, which may result in an increase in their consumption tax.

 

The revision of the Public Health Law by the Indonesian government is a significant step towards improving health regulations and ensuring public health safety. The Ministry of Finance is currently conducting research on the various provisions of the bill and plans to make comprehensive tax adjustments to cigarettes and e-cigarettes after the revision is completed.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai
U.S. FDA posts TPSAC meeting materials ahead of discussion on ZYN MRTP applications
U.S. FDA posts TPSAC meeting materials ahead of discussion on ZYN MRTP applications
On January 20, 2026, the U.S. Food and Drug Administration (FDA) posted meeting materials ahead of a virtual Tobacco Products Scientific Advisory Committee (TPSAC) meeting scheduled for January 22, 2026, to discuss modified risk tobacco product (MRTP) applications submitted by Swedish Match USA, Inc. for 20 ZYN nicotine pouch products.
Jan.21 by 2FIRSTS.ai
Vietnam Ho Chi Minh City police seize 28,657 illegal vape-related products worth over US$182,400
Vietnam Ho Chi Minh City police seize 28,657 illegal vape-related products worth over US$182,400
Police in Ho Chi Minh City, Vietnam say they dismantled a large illegal vape distribution ring led by 29-year-old Nguyễn Ngọc Quốc Uy, who allegedly built a concealed “secret room” to hide contraband. Officers seized 28,657 items valued at more than VND 4.8 billion (about US$182,400).
Feb.04 by 2FIRSTS.ai
Imperial Brands names John Rishton chair-designate, to take over as chair in December 2026
Imperial Brands names John Rishton chair-designate, to take over as chair in December 2026
Imperial Brands said in a statement on its website that John Rishton will join the board in July 2026 and assume the role of chair in December, succeeding current chair Thérèse Esperdy, who will retire at that time.
Jan.21 by 2FIRSTS.ai
JT Delivers Record FY2025 Results as RRP Accelerates and Ploom Expands Globally
JT Delivers Record FY2025 Results as RRP Accelerates and Ploom Expands Globally
JT reported record FY2025 revenue and adjusted operating profit, supported by combustible resilience and accelerating reduced-risk product growth. Heated tobacco volumes surged, led by Ploom. The group confirmed a major three-year RRP investment plan and projected further growth in 2026.
Feb.12
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11